Different medical institutions have selected different imported and domestic brand instruments: 38 domestic and 58 imported.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

NEW YORK – Qiagen said on Thursday that it has formed a global strategic alliance with Japan's Sysmex to develop and commercialize cancer companion diagnostics using Sysmex's Plasma-Safe-SeqS next-generation sequencing technology.

On the evening of June 30, it is said that Hotgen Biotech will increase by about ￥1.378 billion yuan to about ￥1.598 billion yuan, with a year-on-year increase of 70546.05% to 81808.47% ,which is Compared with the same period of last year.

Recently, South Korean idol Song Joong Ki endorsed SD BIOSENSOR, an in vitro diagnostic company, sparking heated discussions in the IVD industry.

To date, no immunological data on COVID-19 heterologous vaccination schedules in humans have been reported. We assessed the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Germany) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, UK).

On June 21st, COVID-19 Antigen Rapid Test (Colloidal Gold) COVID-19 Antigen Schnelltest (kolloidales Gold) Probe: Speichel (Spucktest) developed by Joinstar Biomedical Technology obtained the approval of the German Federal Agency for Medicines and Medical Devices to enter the self-testing list.

On June 26, 2021, Shanghai, Sanyou Biopharmaceutical (Shanghai) Co., Ltd. announced the closing of series B financing. This financing round was co-led by LH Ventures and Montesy Investment and followed by Grand Mount Capital and Seeking Capital (an existing investor).

Jun. 22, 2021– PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) is pleased to announce it has entered into an agreement to acquire SIRION Biotech GmbH, a leading, global provider of viral vector. The acquisition is expected to close during the third quarter of 2021.

On June 23, 2021, Suzhou Nanomicro Technology Co., Ltd. was listed on SSE STAR Market. Stock code: 688690. The number of A shares publicly issued this time is 44 million shares, the issue price is 8.07 yuan/share, and the opening price is 93.00 yuan/share.

On the evening of June 21st, Sansure acquired a 14.77% equity interest in GeneMind through equity transfer and subscription of newly added registered capital at a cost of RMB 255.2 million. When the transaction is completed, Sansure will become the second largest shareholder of GeneMind.

JP Morgan and Cowen said on Monday they have initiated coverage of shares of Singular Genomics Systems.JP Morgan gave the shares an Overweight rating and a price target of $30 while Cowen gave them an Outperform rating.